BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...drug discovery include its September partnership with Recursion Pharmaceuticals Inc....
BioCentury | Oct 17, 2020
Finance

Menlo to continue healthcare push at intersection of tech, life sciences with $500M fund

...Dravet syndrome into the clinic. Other portfolio companies include synthetic biology companies Senti Biosciences Inc. and Synthego Corp.; Recursion Pharmaceuticals Inc....
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...lab, including Hydra Biosciences Inc., Navigen Pharmaceuticals Inc. and Recursion Pharmaceuticals Inc....
BioCentury | Sep 9, 2020
Deals

‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

...Capital Management and Samsara BioCapital —joined Recursion Pharmaceuticals Inc.’s...
...to do discover rare disease candidates. Lauren Martz Bayer AG Recursion Pharmaceuticals Inc. Pulmonary Pulmonary...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...guidance; its stock fell 12% in after-hours trading. Recursion takes out digital research play Vium Recursion Pharmaceuticals Inc....
...Dihydroorotate dehydrogenase EGFR (ErbB1; HER1) - Epidermal growth factor receptor BioCentury Staff IMU-838 Spravato, esketamine (jnj-54135419) Immunic Inc. Johnson & Johnson Recursion Pharmaceuticals Inc. Vium...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s First New Partner Since 2017” ). Recursion Pharmaceuticals Inc....
...30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...that trigger immune attack (see "Driving Neoantigen Production via DNA Mismatch Repair" ). AI company Recursion Pharmaceuticals Inc....
...BioCentury Staff National Institute for Health and Care Excellence (NICE) Bristol Myers Squibb Co. NeoPhore Ltd. Medicxi Ventures Leap Therapeutics Inc. Recursion Pharmaceuticals Inc. Achilles...
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...drug discovery. That includes a Phase I trial launch for a repurposing candidate found by Recursion Pharmaceuticals Inc.’s...
BioCentury | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

...with some techniques -- the cells need to be fixed. High throughput single-cell imaging company Recursion Pharmaceuticals Inc....
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...deeper into the clinic. Led by Baillie Gifford’s Scottish Mortgage Investment Trust, the round by Recursion Pharmaceuticals Inc....
Items per page:
1 - 10 of 34
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...drug discovery include its September partnership with Recursion Pharmaceuticals Inc....
BioCentury | Oct 17, 2020
Finance

Menlo to continue healthcare push at intersection of tech, life sciences with $500M fund

...Dravet syndrome into the clinic. Other portfolio companies include synthetic biology companies Senti Biosciences Inc. and Synthego Corp.; Recursion Pharmaceuticals Inc....
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...lab, including Hydra Biosciences Inc., Navigen Pharmaceuticals Inc. and Recursion Pharmaceuticals Inc....
BioCentury | Sep 9, 2020
Deals

‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

...Capital Management and Samsara BioCapital —joined Recursion Pharmaceuticals Inc.’s...
...to do discover rare disease candidates. Lauren Martz Bayer AG Recursion Pharmaceuticals Inc. Pulmonary Pulmonary...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...guidance; its stock fell 12% in after-hours trading. Recursion takes out digital research play Vium Recursion Pharmaceuticals Inc....
...Dihydroorotate dehydrogenase EGFR (ErbB1; HER1) - Epidermal growth factor receptor BioCentury Staff IMU-838 Spravato, esketamine (jnj-54135419) Immunic Inc. Johnson & Johnson Recursion Pharmaceuticals Inc. Vium...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s First New Partner Since 2017” ). Recursion Pharmaceuticals Inc....
...30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...that trigger immune attack (see "Driving Neoantigen Production via DNA Mismatch Repair" ). AI company Recursion Pharmaceuticals Inc....
...BioCentury Staff National Institute for Health and Care Excellence (NICE) Bristol Myers Squibb Co. NeoPhore Ltd. Medicxi Ventures Leap Therapeutics Inc. Recursion Pharmaceuticals Inc. Achilles...
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

...drug discovery. That includes a Phase I trial launch for a repurposing candidate found by Recursion Pharmaceuticals Inc.’s...
BioCentury | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

...with some techniques -- the cells need to be fixed. High throughput single-cell imaging company Recursion Pharmaceuticals Inc....
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...deeper into the clinic. Led by Baillie Gifford’s Scottish Mortgage Investment Trust, the round by Recursion Pharmaceuticals Inc....
Items per page:
1 - 10 of 34